Would you offer adjuvant chemotherapy, osimertinib, or both to a patient with Stage IB EGFR mutated lung adenocarcinoma found in the lung explant pathology after bilateral lung transplant?
Would you consider the immune suppressed status of the patient as a high risk factor to offer adjuvant therapy?
Community PollStarted
What would your adjuvant approach be for a patient with Stage IB EGFR mutated lung adenocarcinoma on immunosuppression for organ transplant?
21 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Colorado Anschutz Medical Center
Answered on
This is such a rare and individualized case that there will likely be no correct answer. My understanding of the facts is that stage IB lung adenocarcinoma was found on the removed explanted lung after a lung transplant. The question posed is what is the role of adjuvant systemic therapy? Ignoring t...
Join for free or sign in to see the full answer